Ventyx Biosciences Valuation
| VTYX Stock | USD 2.05 0.11 5.67% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Ventyx Biosciences has a current Real Value of $4.28 per share. The regular price of the company is $2.05. Our model measures the value of Ventyx Biosciences from inspecting the company fundamentals such as Shares Owned By Institutions of 84.72 %, shares outstanding of 70.71 M, and Return On Equity of -0.54 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ventyx Biosciences' valuation include:
Undervalued
Today
Please note that Ventyx Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Ventyx Biosciences is based on 3 months time horizon. Increasing Ventyx Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ventyx Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ventyx Stock. However, Ventyx Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.05 | Real 4.28 | Target 11.14 | Hype 2.05 | Naive 2.04 |
The intrinsic value of Ventyx Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Ventyx Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Ventyx Biosciences helps investors to forecast how Ventyx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ventyx Biosciences more accurately as focusing exclusively on Ventyx Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ventyx Biosciences' intrinsic value based on its ongoing forecasts of Ventyx Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ventyx Biosciences' closest peers.
Ventyx Biosciences Cash |
|
Ventyx Valuation Trend
Analysing the historical paterns of Ventyx Biosciences' enterprise value and its market capitalization is a good way to estimate and gauge the value of Ventyx Biosciences over time and is usually enough for investors to make rational market timing decisions.
Ventyx Biosciences Total Value Analysis
Ventyx Biosciences is at this time anticipated to have valuation of (126.61 M) with market capitalization of 144.96 M, debt of 12.51 M, and cash on hands of 250.45 M. The negative valuation of Ventyx Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Ventyx Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(126.61 M) | 144.96 M | 12.51 M | 250.45 M |
Ventyx Biosciences Asset Utilization
One of the ways to look at asset utilization of Ventyx is to check how much profit was generated for every dollar of assets it reports. Ventyx Biosciences has a negative utilization of assets of -0.33 %, losing $0.003339 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Ventyx Biosciences shows how discouraging it operates for each dollar spent on its assets.Ventyx Biosciences Ownership Allocation
Ventyx Biosciences shows a total of 70.71 Million outstanding shares. The majority of Ventyx Biosciences outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Ventyx Biosciences to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Ventyx Biosciences. Please pay attention to any change in the institutional holdings of Ventyx Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Ventyx Biosciences Profitability Analysis
Net Loss for the year was (192.96 M) with profit before overhead, payroll, taxes, and interest of 0.About Ventyx Biosciences Valuation
Our relative valuation model uses a comparative analysis of Ventyx Biosciences. We calculate exposure to Ventyx Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ventyx Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -846.9 K | -804.6 K |
Ventyx Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 58.5 M |
Ventyx Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Ventyx Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ventyx we look at many different elements of the entity such as Ventyx's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ventyx Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ventyx Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ventyx Biosciences' worth.Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.